Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Single-agent Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification

NCT02626364 is registered in ClinicalTrials.gov with Arog Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02626364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02626364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Single-agent Crenolanib in Recurrent/Refractory Glioblastoma With PDGFRA Gene Amplification
Lead sponsor
Arog Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2016
Completion date
July 31, 2020
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent/refractory glioblastoma